GHO Capital, The Vistria Group Acquire Alcami


Purchase will help CDMO expand into European market

GHO Capital Partners LLP, a healthcare investor, and The Vistria Group, a private investment firm, have entered into a definitive agreement to acquire a controlling interest in Alcami, a contract development and manufacturing organization (CDMO). The parties will have a 50/50 The controlling interest in the company will be split 50/50 among both parties.

Alcami has built a strong offering, market position, and reputation in high-growth specialties, including drug product manufacturing focusing on sterile fill-finish of both biologics and small molecules; formulation development; lab services; and current good manufacturing practice (cGMP) biostorage of high-value temperature-sensitive biologics, pharmaceuticals, and materials.

“We believe Alcami represents a unique opportunity to acquire a rapidly growing CDMO with complementary capabilities in attractive markets,” comment Mike Mortimer and Alan MacKay, managing partners of GHO Capital. “ … The company is set to accelerate its growth and leveraging our specialist expertise, we are delighted to be supporting them to diversify its product and service mix, pushing into new markets such as Europe.”

Read more about the acquisition here.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.